ENTRY       D10826            Mixture   Drug
NAME        Saxagliptin and dapagliflozin;
            Qtern (TN)
PRODUCT     QTERN (AstraZeneca Pharmaceuticals LP)
COMPONENT   (Saxagliptin [DR:D08996] | Saxagliptin hydrate [DR:D09753] | Saxagliptin hydrochloride [DR:D10262]), (Dapagliflozin [DR:D08897] | Dapagliflozin propanediol [DR:D09763])
CLASS       Antidiabetic agent
             DG02044  Hypoglycemic agent
              DG03035  Combination of DPP-4 inhibitor and SGLT2 inhibitor
REMARK      ATC code: A10BD21
            Product: D10826<US>
EFFICACY    Antidiabetic
  DISEASE   Type 2 diabetes mellitus [DS:H00409]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A10 DRUGS USED IN DIABETES
               A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
                A10BD Combinations of oral blood glucose lowering drugs
                 A10BD21 Saxagliptin and dapagliflozin
                  D10826  Saxagliptin and dapagliflozin &lt;US&gt;
            USP drug classification [BR:br08302]
             Blood Glucose Regulators
              Antidiabetic Combinations
               Dapagliflozin/ Saxagliptin
                D10826  Saxagliptin and dapagliflozin
            Drug groups [BR:br08330]
             Antidiabetic agent
              DG02044  Hypoglycemic agent
               DG03035  Combination of DPP-4 inhibitor and SGLT2 inhibitor
                D10826  Saxagliptin and dapagliflozin
            Drug classes [BR:br08332]
             Antidiabetic agent
              DG02044  Hypoglycemic agent
               D10826  Saxagliptin and dapagliflozin
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10826
DBLINKS     PubChem: 319902626
///
